Retrophin (RTRX) PT Raised to $40 at BMO Capital

BMO Capital analyst Do Kim reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $40.00 (from $28.00) and increase the probability of success for Sparsentan to 45% from 25%, following positive Phase II DUET data.

Kim commented, "While we model an accelerated approval for Sparsentan, we recognize the increased risk regarding an early filing, given little visibility on the likely commercial dose. Our 45% risk adjustment reflects the potential need for a confirmatory Phase III trial prior to regulatory filing."

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $16.32 yesterday.

You May Also Be Interested In

• Deutsche Bank Upgrades Sirius XM Radio (SIRI) to Buy, 'mispriced based on a large disconnect between consensus estimates and what we believe the company can achieve
• Cambricon Technologies Corp (688256:CH) PT Lowered to RMB2,000 at Macquarie
• Food Empire (FEH:SP) PT Lowered to SGD2.90 at Macquarie